EcoDrugPlus

Sodium Channel Protein Type 4 Subunit Alpha-Like

Ensembl ID : ENSCSEG00000016240
Gene Symbol: LOC103377201
3 Cross references
246 Possible Orthologues:

Sodium Channel Protein Type 8 Subunit Alpha-Like

Ensembl ID : ENSCSEG00000003144
Gene Symbol: LOC103385974
2 Cross references
219 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Xii, Alpha A

Ensembl ID : ENSCSEG00000009036
Gene Symbol: SCN12AA
1 Cross references
245 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSCSEG00000002058
Gene Symbol: SCN8A
2 Cross references
218 Possible Orthologues:

Sodium- And Chloride-Dependent Gaba Transporter 1-Like

Ensembl ID : ENSCSEG00000021432
Gene Symbol: LOC103385534
3 Cross references
204 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSCSEG00000001057
Gene Symbol: LOC103389243
2 Cross references
326 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-2-Like

Ensembl ID : ENSCSEG00000017827
Gene Symbol: LOC103395423
3 Cross references
197 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-233-Like

Ensembl ID : ENSCSEG00000006013
Gene Symbol: LOC103389586
3 Cross references
215 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-3-Like

Ensembl ID : ENSCSEG00000008886
Gene Symbol: LOC103378112
3 Cross references
230 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSCSEG00000015484
Gene Symbol: SLC10A2
3 Cross references
211 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSCSEG00000018239
Gene Symbol: SLC18A2
3 Cross references
216 Possible Orthologues:

Solute Carrier Family 22 Member 6

Ensembl ID : ENSCSEG00000009492
Gene Symbol: SLC22A6
3 Cross references
360 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).